What is the UK PRIMETIME Biomarker Study?
PRIMETIME (ISRCTN 41579286) is a UK-led biomarker-directed clinical trial evaluating the omission of adjuvant radiotherapy in patients with early breast cancer who are considered at very low risk of local relapse. 1
Study Design and Rationale
The PRIMETIME study operates on the principle that for certain patients with early breast cancer at very low risk of local recurrence, the potential harms of radiotherapy may outweigh its benefits. The trial uses biomarkers to identify this specific patient population and tests whether radiotherapy can be safely omitted in these individuals.
Key Features
Patient Population:
- Adults with early breast cancer
- Classified as very low risk for local relapse based on biomarker assessment
- Newly diagnosed cases requiring treatment decisions
Primary Objective: The study evaluates whether biomarker-guided treatment decisions can safely identify patients who may avoid radiotherapy without compromising oncologic outcomes, thereby sparing them from treatment-related toxicity and impact on quality of life.
Embedded Study Within A Trial (SWAT)
PRIMETIME includes an innovative embedded study examining patient decision-making. This SWAT component used a cluster stepped-wedge trial design to investigate whether patient decision aids (PDAs) reduce decisional conflict when patients face choices about radiotherapy omission. 1
The decision aid intervention included:
- Patient information materials and diagrams (standard information)
- An explanatory video detailing risks and benefits of radiotherapy (enhanced information)
- Materials developed collaboratively between patient advocates and trial investigators
Key findings from the SWAT:
- 521 evaluable questionnaires were returned from 809 eligible patients (64% response rate) across 24 clusters
- Decisional conflict scores were low in both groups (mean 10.88 in standard group vs 8.99 in enhanced group)
- No statistically significant difference was found between groups (p=0.09)
- The low decisional conflict levels suggest high-quality baseline information provision
Clinical Significance
This trial represents an important shift toward de-escalation of treatment in carefully selected breast cancer patients, prioritizing quality of life while maintaining oncologic safety. The biomarker-stratified approach aligns with precision medicine principles, using molecular characteristics to guide individualized treatment decisions rather than applying uniform treatment to all patients with early breast cancer.
The embedded decision aid study demonstrates the importance of patient-centered information provision in trials involving treatment de-escalation, where patients must weigh potential risks of recurrence against immediate treatment-related toxicity.